07.08.16
BioInvent International has signed an agreement with Alligator Bioscience AB to provide process development and manufacturing services for Alligator’s new bispecific antibody, ADC-1015.
The agreement includes payments for development services and GMP manufacturing for the upcoming clinical trial. Financial details were not disclosed.
“The agreement with Alligator to manufacture its new bispecific antibody ADC-1015 speaks to our leading expertise when it comes to manufacturing of antibodies. Our manufacturing facility will be upgraded during 2016, which includes installation of a Single Use Bioreactor (SUB). This enables delivery according to timelines defined by Alligator. The agreement is expected to generate revenues of more than SEK 20 million,” said Michael Oredsson, president and chief executive officer of BioInvent.
“We are pleased that BioInvent has committed to process development and manufacturing of the bispecific immune-activating antibody ADC-1015. BioInvent's long experience and upgraded GMP certified manufacturing facility meet our needs for the coming clinical trial and will enable us to move ADC-1015 through to the clinic according to plan,” said Per Norlén, chief executive officer of Alligator Bioscience AB.
The agreement includes payments for development services and GMP manufacturing for the upcoming clinical trial. Financial details were not disclosed.
“The agreement with Alligator to manufacture its new bispecific antibody ADC-1015 speaks to our leading expertise when it comes to manufacturing of antibodies. Our manufacturing facility will be upgraded during 2016, which includes installation of a Single Use Bioreactor (SUB). This enables delivery according to timelines defined by Alligator. The agreement is expected to generate revenues of more than SEK 20 million,” said Michael Oredsson, president and chief executive officer of BioInvent.
“We are pleased that BioInvent has committed to process development and manufacturing of the bispecific immune-activating antibody ADC-1015. BioInvent's long experience and upgraded GMP certified manufacturing facility meet our needs for the coming clinical trial and will enable us to move ADC-1015 through to the clinic according to plan,” said Per Norlén, chief executive officer of Alligator Bioscience AB.